Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Exelixis Sank Today

By Brian Orelli, PhD - Updated Nov 1, 2019 at 2:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A slowdown in the biotech’s main franchise shouldn’t have come as a surprise.

What happened

Shares of Exelixis (EXEL -0.41%) are down 10% at 1:15 p.m. EDT following the release of third-quarter earnings yesterday after the bell.

So what

Product revenue, which mostly comes from sales of Exelixis' liver and kidney cancer drug Cabometyx, came in at $191.8 million, a 17.7% year-over-year increase. While that's certainly solid growth on a yearly basis, it's down slightly from the $193.7 million in product sales Exelixis registered in the second quarter. And when you factor in a price increase, Cabometyx demand was down 4% quarter over quarter.

Doctor showing a report to a patient in a hospital bed.

Image source: Getty Images.

Total revenue beat analyst expectations, but that was due to a one-time $50 million milestone payment from Exelixis' international partner Ipsen Pharma for achieving $250 million in sales over four consecutive fiscal quarters.

On the bottom line, Exelixis earned $0.31 per share, which has come down from $0.41 per share in the year-ago quarter as the biotech has dramatically ramped up spending on research and development to replenish its pipeline.

Now what

The slowdown in growth of Cabometyx is disappointing but not particularly surprising after the FDA approved combination treatments -- Merck's (MRK -0.46%) Keytruda plus Pfizer's (PFE -0.72%) Inlyta and Pfizer and Merck KgaA's Bavencio plus Inlyta -- for patients with kidney cancer.

Fortunately, Exelixis has its own Cabometyx combination, with Bristol-Myers Squibb's (BMY -1.38%) Opdivo, in development. Data from the phase 3 CheckMate 9ER are expected in early 2020 and, with a quick approval, could help restart substantial sales growth later next year.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
$19.40 (-0.41%) $0.08
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.75 (-0.72%) $0.36
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$90.60 (-0.46%) $0.42
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.53 (-1.38%) $-1.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.